5245

524412

AAREYDRUGS

img img img img
No Data Available

AAREY DRUGS & PHARM LTD Share Price Update

As of the latest trading session, AAREY DRUGS & PHARM LTD share price is currently at ₹69.67, which is down by ₹-7.06 from its previous closing. Today, the stock has fluctuated between ₹69.06 and ₹75.00. Over the past year, AAREY DRUGS & PHARM LTD has achieved a return of 96.08%. In the last month alone, the return has been 12.98%.

AAREY DRUGS & PHARM LTD performance

Today’s low

Today’s high

₹ 69.06 ₹ 75.00
₹ 69.67

52 week low

52 week high

₹ 31.35 ₹ 100.00
₹ 69.67

Open Price

₹ 74.94

Prev. Close

₹ 76.73

Volume (Shares)

122080.00

Total traded value

₹ 85.05

Upper Circuit

₹ 84.40

Lower Circuit

₹ 69.06

info

Investment Returns

Over 1 Month [-]% Over 3 Months [-]% Over 6 Months [-]% Over 1 Year [-]%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

AAREY DRUGS & PHARM LTD fundamentals


  • Market cap (Cr)

    197.50

  • P/E Ratio (TTM)

    63.69

  • Beta

    0.91

  • Book Value / share

    51.13

  • Return on equity

    2.96%

  • EPS (TTM)

    1.21

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.57

info icon alternate text
  • Market cap (Cr)

    199.20

  • P/E Ratio (TTM)

    63.69

  • Beta

    0.88

  • Book Value / share

    51.13

  • Return on equity

    2.96%

  • EPS (TTM)

    1.21

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    0.57

info icon alternate text

AAREY DRUGS & PHARM LTD Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2025 (Values in Cr)
Revenue 96.43
Operating Expense 99.69
Net Profit 0.57
Net Profit Margin (%) 0.59
Earnings Per Share (EPS) 0.20
EBITDA 2.67
Effective Tax Rate (%) 38.04
Particulars SEP 2025 (Values in Cr)
Revenue 84.16
Operating Expense 83.47
Net Profit 1.02
Net Profit Margin (%) 1.21
Earnings Per Share (EPS) 0.36
EBITDA 3.43
Effective Tax Rate (%) 31.08
Particulars JUN 2025 (Values in Cr)
Revenue 102.21
Operating Expense 102.03
Net Profit 1.37
Net Profit Margin (%) 1.34
Earnings Per Share (EPS) 0.48
EBITDA 3.26
Effective Tax Rate (%) 20.80
Particulars MAR 2025 (Values in Cr)
Revenue 108.10
Operating Expense 114.00
Net Profit 0.47
Net Profit Margin (%) 0.43
Earnings Per Share (EPS) 0.17
EBITDA 3.34
Effective Tax Rate (%) 70.55
Particulars DEC 2024 (Values in Cr)
Revenue 133.79
Operating Expense 133.07
Net Profit 0.72
Net Profit Margin (%) 0.53
Earnings Per Share (EPS) 0.26
EBITDA 2.88
Effective Tax Rate (%) 48.57
Particulars MAR 2025 (Values in Cr)
Revenue 473.94
Operating Expense 477.65
Net Profit 4.02
Net Profit Margin (%) 0.84
Earnings Per Share (EPS) 1.43
EBITDA 12.70
Effective Tax Rate (%) 34.09
Particulars MAR 2024 (Values in Cr)
Revenue 395.62
Operating Expense 397.24
Net Profit 4.68
Net Profit Margin (%) 1.18
Earnings Per Share (EPS) 1.84
EBITDA 11.42
Effective Tax Rate (%) 12.35
Particulars MAR 2023 (Values in Cr)
Revenue 418.96
Operating Expense 415.67
Net Profit 3.78
Net Profit Margin (%) 0.90
Earnings Per Share (EPS) 1.49
EBITDA 10.46
Effective Tax Rate (%) 37.20
Particulars MAR 2022 (Values in Cr)
Revenue 492.68
Operating Expense 485.40
Net Profit 6.54
Net Profit Margin (%) 1.32
Earnings Per Share (EPS) 2.72
EBITDA 14.02
Effective Tax Rate (%) 34.69
Particulars MAR 2021 (Values in Cr)
Revenue 348.42
Operating Expense 347.13
Net Profit 6.51
Net Profit Margin (%) 1.86
Earnings Per Share (EPS) 2.79
EBITDA 11.65
Effective Tax Rate (%) 21.56
Particulars MAR 2025 (Values in Cr)
Book Value / Share 46.90
ROE % 2.96
ROCE % 6.38
Total Debt to Total Equity 0.24
EBITDA Margin 2.68
Particulars MAR 2024 (Values in Cr)
Book Value / Share 45.57
ROE % 3.74
ROCE % 6.09
Total Debt to Total Equity 0.28
EBITDA Margin 2.89
Particulars MAR 2023 (Values in Cr)
Book Value / Share 44.43
ROE % 3.26
ROCE % 6.28
Total Debt to Total Equity 0.22
EBITDA Margin 2.49
Particulars MAR 2022 (Values in Cr)
Book Value / Share 43.85
ROE % 6.16
ROCE % 9.79
Total Debt to Total Equity 0.15
EBITDA Margin 2.86
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.29
ROE % 6.81
ROCE % 9.38
Total Debt to Total Equity 0.19
EBITDA Margin 3.35
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 1.47
Total Assets 290.59
Total Liabilities 290.59
Total Equity 138.48
Share Outstanding 2
Price to Book Ratio 0.72
Return on Assets (%) 1.38
Return on Capital (%) 2.32
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1.59
Total Assets 303.29
Total Liabilities 303.29
Total Equity 132.77
Share Outstanding 2
Price to Book Ratio 0.98
Return on Assets (%) 1.54
Return on Capital (%) 2.85
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 0.70
Total Assets 291.32
Total Liabilities 291.32
Total Equity 117.40
Share Outstanding 2
Price to Book Ratio 0.53
Return on Assets (%) 1.29
Return on Capital (%) 2.43
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.19
Total Assets 245.16
Total Liabilities 245.16
Total Equity 113.63
Share Outstanding 2
Price to Book Ratio 0.94
Return on Assets (%) 2.67
Return on Capital (%) 5.13
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.64
Total Assets 233.03
Total Liabilities 233.03
Total Equity 98.86
Share Outstanding 2
Price to Book Ratio 0.56
Return on Assets (%) 2.79
Return on Capital (%) 5.57
Particulars MAR 2025 (Values in Cr)
Net Income 6.10
Cash from Operations 12.20
Cash from Investing -5.93
Cash from Financing -4.48
Net change in Cash -0.12
Free Cash Flow 17.41
Particulars MAR 2024 (Values in Cr)
Net Income 5.34
Cash from Operations -1.66
Cash from Investing -1.70
Cash from Financing 5.58
Net change in Cash 0.88
Free Cash Flow -0.94
Particulars MAR 2023 (Values in Cr)
Net Income 6.00
Cash from Operations 0.99
Cash from Investing 0.44
Cash from Financing 1.35
Net change in Cash 0.51
Free Cash Flow 2.04
Particulars MAR 2022 (Values in Cr)
Net Income 10.02
Cash from Operations 4.08
Cash from Investing -3.21
Cash from Financing 2.25
Net change in Cash -0.45
Free Cash Flow 6.29
Particulars MAR 2021 (Values in Cr)
Net Income 8.30
Cash from Operations 7.14
Cash from Investing -2.87
Cash from Financing -2.45
Net change in Cash 0.14
Free Cash Flow 10.02
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.24 11.36 1.36 201.09 23.12 / 42.05
BLISS GVS PHARMA LTD 211.90 20.26 1.97 2241.67 105.05 / 244.05
CIPLA LTD 1347.65 22.90 3.30 108860.56 1283.00 / 1672.20
FERMENTA BIOTECH LIMITED 325.35 10.82 2.44 957.54 219.00 / 399.00
GLAXOSMITHKLINE PHARMA LT 2570.00 43.29 25.49 43537.35 2220.00 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 26.24 25.23 3.65 201.09 23.12 / 42.05
AMRUTAJAN HEALTH LTD 593.20 29.66 5.01 1714.98 548.05 / 789.95
ASTRAZENECA PHARMA IND LT 8842.60 106.27 27.66 22106.50 6501.60 / 10653.05
BLISS GVS PHARMA LTD 211.90 28.87 2.03 2241.67 105.05 / 244.05

AAREY DRUGS & PHARM LTD shareholding pattern

Holding

57.08%
39.05%
3.85%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

AAREY DRUGS & PHARM LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
69.67 -9.20 redarrow
red-green-graph indicator
15 Bearish
1 Bullish
  • 5 Days 76.00
  • 26 Days 71.20
  • 10 Days 74.30
  • 50 Days 71.30
  • 12 Days 73.60
  • 100 Days 72.30
  • 20 Days 71.90
  • 200 Days 69.90
77.00 PIVOT

First Support

75.73

First Resistance

78.01

Second Support

74.72

Second Resistance

79.28

Third Support

73.45

Third Resistance

80.29

RSI

57.49

ADX

19.42

MACD

2.40

Williams % R

-43.17

Commodity Channel Index (CCI)

112.03

Date

2026-02-27

Week

225900.00

Same Day

142357.00

Month

172974.00

1 Year

0.92

3 Year

0.87

Over 1 Month

12.98%

down

Over 1 Year

96.08%

down

Over 3 Months

-12.99%

down

Over 3 Years

40.27%

down

Over 6 Months

30.55%

down

Over 5 Years

12.09%

down

AAREY DRUGS & PHARM LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
13 Dec 2018 0.1 Interim 14 Dec 2018 Equity shares
Ex-Date Ex-Bonus Ratio
26 Jun 2012 25 Jun 2012 1:5
Dividend date Dividend amount Dividend type Record date Instrument type
13 Dec 2018 0.1 Interim 14 Dec 2018 Equity shares
Ex-Date Ex-Bonus Ratio
26 Jun 2012 25 Jun 2012 1:5

Top Gainers

AAREY DRUGS & PHARM LTD Share Price

Aarey Drugs & Pharmaceuticals Limited was originally incorporated on May 15, 1990 as a private limited company in Mumbai with the name Niharika Textiles & Chemicals Private Limited. The company was originally promoted by Prakash Mandhana, Kavita Mandhana and Neeta Mandhana. In March, 1993, the Aarey Group of companies belonging to Ghatalia family took over the Company and it was converted into public limited company. Also, the name of the company was changed from Niharika Textiles & Chemicals Private Limited to Aarey Drugs & Pharmaceuticals Limited.

The Company is one of the manufacturer and suppliers of pharmaceutical raw materials, Chemicals, Pharmaceuticals ingredients, API's Drugs, Food Colours and Flavours. The company is engaged in the business of manufacturing, selling of drugs & pharmaceutical products and is governed by a number of central and state legislations that regulate the business. Apart from the bulk drug manufacturing activity, they also undertake importing & distributing of various industrial chemicals & solvents throughout the country. The company has their manufacturing unit located at Thane.

The company's products include Methyl Nitro Imidazole, Metronidazole & Metronidazole Benzoate. Their pharmaceutical products are sourced from the authentic vendors to assure the quality and effectiveness. The pharmaceutical products offered by the company are in compliance with IP/ BP/ CP/ USP standards. he Company maintains its head office in Masjid, Mumbaiand the plant in Tarapur, Maharashtra.

The company was established with the main object setting up manufacturing facilities for Bulk Drugs. In the year 1993, the company came with a public issue of 27,50,000 equity shares of Rs 10 each for cash at par aggregating to Rs 275 lakh. Also, the company shares were listed on the BSE, ASE & DSE.

In May 2009, the company plant started to upgrade the existing plant into international standards.

In June 2016, the Company commenced manufacturing of Mono Methyl Urea & Di Methyl Urea. In 2017-18, it added new products i.e. Erithromycin Derivates & Mafenamic Acid with capacity of 10 m.t. & 25 m.t. respectively in June' 2017.

In 2018-19, it commenced manufacturing of products i.e. Ortho Para Nitro Anisole, 2-Bromomethyl-1,3 dioxolane, and Mefenamic Acid. It also commenced manufacturing products i.e.Metformin & Urasil.

Parent organization Indian Private
NSE symbol AAREYDRUGS
Founded 1990
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Aarey Drugs & Pharmaceuticals Ltd?

Answer Field

Aarey Drugs & Pharmaceuticals Ltd share price is for NSE ₹ 69.67 & for BSE ₹ 70.26 as on Mar 02 2026 03:30 PM.

What is the Market Cap of Aarey Drugs & Pharmaceuticals Ltd Share?

Answer Field

The market cap of Aarey Drugs & Pharmaceuticals Ltd for NSE ₹ 197.50 & for BSE ₹ 0.00 as on Mar 02 2026 03:30 PM.

What is the 52 Week High and Low of Aarey Drugs & Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Aarey Drugs & Pharmaceuticals Ltd for NSE is ₹ 100.00 and ₹ 31.35 and for BSE is ₹ 100.00 and ₹ 31.30.

What is 1 year return for Aarey Drugs & Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 96.08%.

What is the P/E Ratio of Aarey Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Mar 02 2026 03:30 PM the price-to-earnings (PE) ratio for Aarey Drugs & Pharmaceuticals Ltd share is 63.69.

What is the PB ratio of Aarey Drugs & Pharmaceuticals Ltd Share?

Answer Field

As on Mar 02 2026 03:30 PM, the price-to-book (PB) ratio for Aarey Drugs & Pharmaceuticals Ltd share is 51.13.

How to Buy Aarey Drugs & Pharmaceuticals Ltd Share?

Answer Field

You can trade in Aarey Drugs & Pharmaceuticals Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Aarey Drugs & Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Aarey Drugs & Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Aarey Drugs & Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59